Sfoglia per Autore "Dalekos, G."
Items 1-20 di 24
-
Anti-cardiolipin antibodies (anti-CL) in patients with hepatitis C virus (HCV) infection are independent of beta2-glycoprotein I (b2GPI) co-factor or features of antiphospholipid syndrome (APS)
Zachou, K.; Liaskos, C.; Christodoulou, D.; Kardasi, M.; Papadamou, G.; Gatselis, N.; Gerovasilis, F.; Tsianos, E.; Dalekos, G. (2002) -
ANTI-HDV-IGM TESTING IN HEPATITIS DELTA REVISITED: CORRELATIONS WITH DISEASE ACTIVITY AND RESPONSE TO PEGYLATED INTERFERON ALFA-2A TREATMENT
Mederacke, I.; Yurdaydin, C.; Bremer, B.; Cakaloglu, Y.; Erhardt, A.; Yalcin, K.; Zachou, K.; Gurel, S.; Heidrich, B.; Dalekos, G.; Dienes, H. P.; Manns, M. P.; Wedemeyer, H. (2010) -
Antibodies to hepatitis E virus among hemodialysis patients: An epidemiological survey in central Greece
Stefanidis, L.; Zerbou, E.; Rizos, C.; Liaskos, C.; Syrganis, C.; Dalekos, G. (2003) -
The antiviral response to tenofovir disoproxil fumarate (TDF) is comparable in lamivudine (LAM)-naive and LAM-experienced subjects treated for chronic hepatitis B (CHB)
Manns, M.; Jeffers, L.; Dalekos, G.; Berg, T.; Trepo, C.; Roberts, S.; Prieto, M.; Rizzetto, M.; Sorbel, J.; Anderson, J.; Mondou, E.; Rousseau, F. (2008) -
Caffeine metabolism in liver cirrhosis
Begas, E.; Asprodini, E. K.; Papakosta, S.; Maglaras, L.; Benakis, A.; Dalekos, G. (2005)Caffeine is metabolized primarily by CYP1A2. Several methods have been developed for the in vivo assessment of CYP1A2 activity using caffeine as a probe drug (2). These methods include the determination of caffeine clearance ... -
Clinical immunology quiz - Case 1
Speletas, M.; Kalala, F.; Dalekos, G. (2007) -
Cross-genotype-reactivity of the immunodominant HCV-CD8 T-cell epitope NS3-1073: Significance for the development of peptide-based vaccines against HCV
Fytili, P.; Dalekos, G.; Cornberg, M.; Schlaphoff, V.; Zauner, W.; Zachou, K.; Manus, M. P.; Klade, C.; Wedemeyer, H. (2006) -
Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis
Liu, J. Z.; Hov, J. R.; Folseraas, T.; Ellinghaus, E.; Rushbrook, S. M.; Doncheva, N. T.; Andreassen, O. A.; Weersma, R. K.; Weismüller, T. J.; Eksteen, B.; Invernizzi, P.; Hirschfield, G. M.; Gotthardt, D. N.; Pares, A.; Ellinghaus, D.; Shah, T.; Juran, B. D.; Milkiewicz, P.; Rust, C.; Schramm, C.; Muler, T.; Srivastava, B.; Dalekos, G.; Nöthen, M. M.; Herms, S.; Winkelmann, J.; Mitrovic, M.; Braun, F.; Ponsioen, C. Y.; Croucher, P. J. P.; Sterneck, M.; Teufel, A.; Andrew, L. Mason; Saarela, J.; Leppa, V.; Dorfman, R.; Alvaro, D.; Floreani, A.; Onengut-Gumuscu, S.; Rich, S. S.; Thompson, W. K.; Schork, A. J.; Næss, S.; Thomsen, I.; Mayr, G.; König, I. R.; Hveem, K.; Cleynen, I.; Gutierrez-Achury, J.; Ricaño-Ponce, I.; Van Heel, D.; Björnsson, E.; Sandford, R. N.; Durie, P. R.; Melum, E.; Vatn, M. H.; Silverberg, M. S.; Duerr, R. H.; Padyukov, L.; Brand, S.; Sans, M.; Annese, V.; Achkar, J. P.; Boberg, K. M.; Marschall, H. U.; Chazouillères, O.; Bowlus, C. L.; Wijmenga, C.; Schrumpf, E.; Vermeire, S.; Albrecht, M.; Rioux, J. D.; Alexander, G.; Bergquist, A.; Cho, J.; Schreiber, S.; Manns, M. P.; Färkkilä, M.; Dale, A. M.; Chapman, R. W.; Konstantinos, N. Lazaridis; Franke, A.; Anderson, C. A.; Karlsen, T. H. (2013)Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation. We compared 3,789 PSC cases of ... -
Dissemination of Methicillin-Susceptible CC398 Staphylococcus aureus Strains in a Rural Greek Area
Sarrou, S.; Liakopoulos, A.; Chasioti, M.; Foka, A.; Fthenakis, G.; Billinis, C.; Spyrou, V.; Pantelidi, K.; Roussaki-Schulze, A.; Lachanas, V.; Makaritsis, K.; Skoulakis, C.; Daikos, G. L.; Dalekos, G.; Spiliopoulou, I.; Petinaki, E. (2015)A large collection of Staphylococcus aureus including a. 745 clinically significant isolates that were consecutively recovered from human infections during 2012-2013, b. 19 methicillin- susceptible (MSSA), randomly selected ... -
Double reactivity against actin and alpha-actinin defines a severe form of autoimmune hepatitis type 1
Gueguen, P.; Dalekos, G.; Nousbaum, J. B.; Zachou, K.; Putterman, C.; Youinou, P.; Renaudineau, Y. (2006)Anti-filamentous actin antibodies characterize autoimmune hepatitis type 1 (AIH-1). Recently, the binding domain of alpha-actinin on actin was shown to be a predominant epitope. To test this reactivity, an anti-alpha-actinin ... -
Epidemiology and natural course of hepatitis C in Greece: Results of the nationwide HEPNET Greece Cohort Study
Raptopoulou, M.; Tzoumakliotis, D.; Nikolopoulou, G.; Skoutelis, A.; Dalekos, G.; Dimopoulou, M.; Angelidou, K.; Avgerinos, A.; Chatzis, G.; Manotakopoulos, S. (2006) -
Genotype 4 HCV infection is difficult to cure with pegylated interferon and ribavirin. Results from a Greek Nationwide Cohort Study
Anagnostou, O.; Manolakopoulos, S.; Bakoyannis, G.; Papatheodoridis, G.; Zisouli, A.; Raptopoulou-Gigi, M.; Manesis, E.; Ketikoglou, I.; Dalekos, G.; Gogos, C.; Vassiliadis, T.; Tzourmakliotis, D.; Karatapanis, S.; Kanatakis, S.; Zoumpoulis-Vafiadis, I.; Hounta, A.; Koutsounas, S.; Giannoulis, G.; Tassopoulos, N.; Touloumi, G. (2014)Background and aim: Patients with genotype 4 (G4) chronic hepatitis C (CHC) are considered a difficult to treat population, although current data on G4 treatment responsiveness and duration are controversial. Greece ... -
HBSAG LEVELS DECLINE DURING PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B FAVORS 6 MONTHS POST-TREATMENT RESPONSE: PERSEAS COHORT INTERIM ANALYSIS
Goulis, I.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G.; Raptopoulou-Gigi, M.; Mimidis, K.; Germanidis, G.; Triantos, C.; Drakoulis, C.; Chounta, A.; Tsoplou, F.; Zintzaras, E.; Bakalos, G.; Papatheodoridis, G. (2012) -
HBSAG LEVELS DURING THE FIRST 24 WEEKS OF PEGINTERFERON ALFA-2A 40KD (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITIS B: THE PERSEAS COHORT
Goulis, I.; Akriviadis, E.; Karatapanis, S.; Deutsch, M.; Dalekos, G.; Raptopoulou-Gigi, M.; Drakoulis, C.; Bakalos, G.; Papatheodoridis, G. (2011) -
HEPATOCELLULAR CARCINOMA (HCC) RISK IN HBeAg-NEGATIVE CHRONIC HEPATITIS B (CHBe-) WITH OR WITHOUT CIRRHOSIS TREATED WITH ENTECAVIR: RESULTS OF THE NATIONWIDE HepNet.Greece COHORT STUDY
Papatheodoridis, G.; Manolakopoulos, S.; Touloumi, G.; Nikolopoulou, G.; Raptopoulou-Gigi, M.; Gogos, C.; Vafiadis-Zouboulis, I.; Karamanolis, D.; Chouta, A.; Ilias, A.; Drakoulis, C.; Mimidis, K. M.; Ketikoglou, I.; Manesis, E.; Mela, M.; Hatzis, G.; Dalekos, G.; HepNet Greece Study, Grp (2013) -
How common are connective tissue disorders in patients with autoimmune hepatitis?
Rigopoulou, E. I.; Dalekos, G.; Bogdanos, D. P. (2007) -
Multiple sclerosis and autoimmune liver diseases
Aggelakis, K.; Tsimourtou, V.; Rigopoulou, E.; Noulas, G.; Dardiotis, E.; Dalekos, G.; Papadimitriou, A.; Hadjigeorgiou, G. (2005) -
Occult hepatitis B virus (HBV) infection in Greek patients with chronic hepatitis C (HCV): A pilot study
Zachou, K.; Liaskos, C.; Makri, E.; Dalekos, G. (2002) -
Prevalence and clinical course of hepatitis delta infection in Greece: A 13-year prospective study
Manesis, E. K.; Vourli, G.; Dalekos, G.; Vasiliadis, T.; Manolaki, N.; Hounta, A.; Koutsounas, S.; Vafiadis, I.; Nikolopoulou, G.; Giannoulis, G.; Germanidis, G.; Papatheodoridis, G.; Touloumi, G. (2013)Background & Aims: Hepatitis D virus (HDV) has decreased in Europe, but recent reports indicate a rising trend. We report the epidemiological changes, clinical progress, and effect of treatment on the natural course of HDV ... -
Retinoid Metabolism in Autoimmune Liver Disease
Giagoudis, A.; Kaffe, E.; Menounou, T.; Dalekos, G.; Moulas, A. N. (2012)